Lytix Biopharma third quarter 2022 results
17 Nov 2022
Phase 2Phase 1Executive ChangeFinancial StatementImmunotherapy
OSLO, Norway, Nov. 17, 2022 /PRNewswire/ -- Lytix Biopharma ("Lytix") (Euronext Growth Oslo: LYTIX), a Norwegian immune-oncology company, today releases its third quarter 2022 results. Highlights include regulatory approval received to expand our ATLAS-IT-05 study to three European countries and the appointment of Stephen Worsley as CBO.
"We are very pleased to now being able to include patients from Spain, France and Norway in our Phase II study. The expansion of the site network will mitigate recruitment challenges, drive enrollment towards completion and extend the clinical impact field for LTX-315", says CEO and Co-founder of Lytix Biopharma, Øystein Rekdal.
Highlights from the third quarter 2022:
Regulatory approval received to expand the ATLAS-IT-05 study to three European countries (Norway, France and Spain)
Verrica Pharmaceuticals is in good progress with their Phase II study in BCC, and the conclusion of part 1 of three parts is expected in Q1 2023
IND enabling activities required to start a Phase I study with LTX-401 is progressing as planned
Stephen Worsley appointed as Chief Business Officer (CBO), and he is already introducing Lytix to KOLs and companies within the industry
Post-period events:
Additional study sites opened in Europe to support ATLAS-IT-05 patient recruitment
ATLAS-IT-04 Clinical Study Report completed
Financial:
Total operating expenses for the six months that ended September 30 are in line with the same period last year, and as a clinical drug development company, R&D efforts represent the majority of our expenses.
A portion of the excess liquidity has been placed in a liquidity fund explaining the increase in short-term financial investments.
At the end of the period cash plus short-term financial investments was NOK 172 million.
Key figures (unaudited):
Government grants recognized in profit and loss, part of Other operating Income, for Q2 2022 was reported at NOK 805 thousand which was NOK 750 thousand lower than actual. The correct amount is NOK 1,555 thousand. The figures in this report are correct, but the YTD figures will therefore not be reconcilable with the H1 report without adjusting for this error.
The results will be presented in a webcast with CEO Øystein Rekdal, CDO Graeme Currie and CFO Gjest Breistein today at 14.30 CEST.
The presentation and subsequent Q&A session will be held in English and may be viewed live at https://channel.royalcast.com/landingpage/hegnarmedia/20221117_4/
A recording of the presentation will be made available on https://www.lytixbiopharma.com/investors/overview.html after the presentation.
For more information, please contact:
Gjest Breistein,
CFO: [email protected]
Ole Peter Nordby,
Head of IR & Communication Manager: [email protected]
SOURCE Lytix Biopharma AS
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.